The effects of mycophenolate mofetil on encapsulated peritoneal sclerosis model in rats

Basit Öğe Kaydı
dc.contributor.authorHur, Ender
dc.contributor.authorBozkurt, Devrim
dc.contributor.authorTimur, Ozge
dc.contributor.authorBicak, Selahattin
dc.contributor.authorSarsik, Banu
dc.contributor.authorAkcicek, Fehmi
dc.contributor.authorDuman, Soner
dc.date.accessioned2019-10-27T21:34:38Z
dc.date.available2019-10-27T21:34:38Z
dc.date.issued2012
dc.departmentEge Üniversitesien_US
dc.description.abstractIntroduction: Encapsulated peritoneal sclerosis (EPS) is a devastating complication of peritoneal dialysis. We aimed to investigate the effects of mycophenolate mofetil (MMF) treatment in experimental EPS in rats. Methods: 40 nonuremic Wistar albino rats were divided equally into 4 groups: control rats received 2 nil isotonic saline intraperitoneally daily for 3 weeks without any other treatment. The chlorhexidine gluconate group received intraperitoneally 2 ml/200 g injection of chlorhexidine gluconate and ethanol dissolved in saline for 3 weeks. The resting group received chlorhexidine gluconate (0 - 3rd week) + peritoneal resting (4th - 6th week). The MMF group received chlorhexidine gluconate (0 - 3rd week) + 125 mg/l MMF in drinking water (4th - 6th week). Dialysate cytokine levels, leukocyte count, peritoneal thickness, inflammation and fibroblast activities were evaluated. Results: Although the MMF and resting groups showed beneficial effects on ultrafiltration and D-1/D-0 glucose compared to the chlorhexidine gluconate group, only MMF treatment improved dialysate TGF-beta 1, VEGF and MCP-1 levels compared to the resting group. Inflammatory activity and vascularity observed in a tissue biopsy, including capillaries number per mm(2) of submesothelial area, decreased in the treatment group. Conclusions: MMF treatment has beneficial effects on EPS via inhibiting inflammation and neovascularisation by reducing dialysate VEGF overexpression.en_US
dc.identifier.doi10.5414/CN107140en_US
dc.identifier.endpage7en_US
dc.identifier.issn0301-0430
dc.identifier.issue1en_US
dc.identifier.pmid22185962en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.5414/CN107140
dc.identifier.urihttps://hdl.handle.net/11454/45645
dc.identifier.volume77en_US
dc.identifier.wosWOS:000299971100001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherDustri-Verlag Dr Karl Feistleen_US
dc.relation.ispartofClinical Nephrologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectmycophenolate mofetilen_US
dc.subjectperitoneal sclerosisen_US
dc.subjectrat modelen_US
dc.titleThe effects of mycophenolate mofetil on encapsulated peritoneal sclerosis model in ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu